JPH08507088A - 免疫応答の増強方法 - Google Patents
免疫応答の増強方法Info
- Publication number
- JPH08507088A JPH08507088A JP7517077A JP51707795A JPH08507088A JP H08507088 A JPH08507088 A JP H08507088A JP 7517077 A JP7517077 A JP 7517077A JP 51707795 A JP51707795 A JP 51707795A JP H08507088 A JPH08507088 A JP H08507088A
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- microparticles
- epitope
- synthetic
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.合成抗原に対するヒト及び動物の免疫応答を増強するにあたり、合成抗原を 先ず生物分解性球状微粒子に埋め込み、その後合成抗原が負荷された微粒子を分 散媒体中に懸濁し、この組成物を非経口的に投与し、その際増強された免疫応答 を発生させることを特徴とする、上記増強方法。 2.合成抗原として少なくとも1個のB-細胞-エピトープ及び少なくとも1個の TH-細胞-エピトープを有する簡単な鎖から成る化合物を使用することを特徴と する、上記方法。 3.合成抗原としてくり返し共有結合されたB-細胞-エピトープ及びTH-細胞- エピトープから成る化合物を使用することを特徴とする、上記方法。 4.合成抗原として細胞毒性T-細胞-エピトープ(Tc)から成る化合物を使用 することを特徴とする、上記方法。 5.合成抗原として、少なくとも1個のTH-及び少なくとも1個のTc-エピトー プの混合物を使用することを特徴とする、上記方法。 6.合成抗原は、原生動物又はウィルス又は細菌又は腫瘍細胞から生じるB-及 びT-細胞-エピトープを含有することを特徴とする、請求の範囲1ないし5のい ずれかに記載の方法。 7.合成抗原は、原生動物又はウィルス又は細菌又は腫瘍細胞から、又はこれら の任意の組合せから生じるB-及びT-細胞-エピトープを含有することを特徴と する、請求の範囲1ないし5のいずれかに記載の方法。 8.球状微粒子は生物分解性バイオポリマーを主成分とし、この際バイオポリマ ーはポリ(乳酸)、ポリ(グリコール酸)、ポリ(乳酸-コ-グリコール酸)、ポ リカプロラクトン、ポリ(ヒドロキシ酪酸)、ポリ(ヒドロキシ酪酸-コ-バレリ アン酸)、ポリオルトエステル又はポリアンヒドライドより成る群から選ばれる ことを特徴とする、請求の範囲1ないし7のいずれかに記載の方法。 9.バイオポリマーは、少なくとも2個の異なるグループから生じることを特徴 とする、請求の範囲8記載の方法。 10.分散媒体として水性又は油状レシチン-液又は水中油型(waessrig-oelige )レシチン-エマルジョンを使用することを特徴とする、請求の範囲1〜9の いずれかに記載の方法。 11.分散媒体としてマイクロエマルジョンを使用することを特徴とする、請求 の範囲1〜9のいずれかに記載の方法。 12.ウィルス、細菌、原生動物又は腫瘍細胞によって引き起こされる疾病に対 してヒト及び動物を免疫化するのに、請求の範囲1〜11のいずれかに記載の方 法を使用する方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH3849/93-6 | 1993-12-23 | ||
CH384993 | 1993-12-23 | ||
PCT/CH1994/000242 WO1995017167A1 (de) | 1993-12-23 | 1994-12-23 | Verfahren zur potenzierung der immunologischen antwort |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH08507088A true JPH08507088A (ja) | 1996-07-30 |
Family
ID=4264801
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP7517077A Ceased JPH08507088A (ja) | 1993-12-23 | 1994-12-23 | 免疫応答の増強方法 |
Country Status (12)
Country | Link |
---|---|
US (1) | US6596278B2 (ja) |
EP (1) | EP0686030B1 (ja) |
JP (1) | JPH08507088A (ja) |
KR (1) | KR100372375B1 (ja) |
CN (1) | CN1120809A (ja) |
AT (1) | ATE199316T1 (ja) |
AU (1) | AU1217395A (ja) |
CA (1) | CA2156718A1 (ja) |
DE (1) | DE59409668D1 (ja) |
DK (1) | DK0686030T3 (ja) |
ES (1) | ES2156932T3 (ja) |
WO (1) | WO1995017167A1 (ja) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU717113B2 (en) | 1995-11-09 | 2000-03-16 | Health Protection Agency | Microencapsulated DNA for vaccination and gene therapy |
US6270795B1 (en) | 1995-11-09 | 2001-08-07 | Microbiological Research Authority | Method of making microencapsulated DNA for vaccination and gene therapy |
US5783567A (en) * | 1997-01-22 | 1998-07-21 | Pangaea Pharmaceuticals, Inc. | Microparticles for delivery of nucleic acid |
EP1787654B1 (en) * | 1997-07-10 | 2013-09-11 | Mannkind Corporation | Intralymphatic immunization for inducing sustained effector CTL responses |
US6977074B2 (en) | 1997-07-10 | 2005-12-20 | Mannkind Corporation | Method of inducing a CTL response |
US6994851B1 (en) | 1997-07-10 | 2006-02-07 | Mannkind Corporation | Method of inducing a CTL response |
US6406719B1 (en) | 1998-05-13 | 2002-06-18 | Microbiological Research Authority | Encapsulation of bioactive agents |
GB9810236D0 (en) | 1998-05-13 | 1998-07-08 | Microbiological Res Authority | Improvements relating to encapsulation of bioactive agents |
CA2335460A1 (en) | 1998-06-18 | 1999-12-23 | Johns Hopkins University School Of Medicine | Polymers for delivery of nucleic acids |
US7087236B1 (en) | 1998-09-01 | 2006-08-08 | Merrion Research I Limited | Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof |
WO2000012124A1 (en) | 1998-09-01 | 2000-03-09 | Elan Corporation, Plc | Oral vaccine compositions |
EP2351577A1 (en) * | 2004-12-29 | 2011-08-03 | Mannkind Corporation | Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs |
WO2007035930A2 (en) * | 2005-09-22 | 2007-03-29 | Prosci Incorporated | Glycosylated polypeptides produced in yeast mutants and methods of use thereof |
WO2007050242A1 (en) * | 2005-10-24 | 2007-05-03 | Staval Pharma, Ltd. | Method for treating/controlling/killing fungi and bacteria |
NZ578285A (en) * | 2007-01-15 | 2011-12-22 | Glaxosmithkline Biolog Sa | Fusion protein comprising a prame linked to a immunological fusion partner protein and additional amino acids at the n terminal end of the fusion partner sequence |
US20090004213A1 (en) | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
US9408906B2 (en) * | 2010-06-04 | 2016-08-09 | Flow Pharma, Inc. | Peptide particle formulation |
CN102901814B (zh) * | 2012-07-12 | 2014-11-26 | 浙江大学 | 莠去津分子印迹金标试纸条及其用途 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4599230A (en) * | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
US5762965A (en) * | 1984-03-16 | 1998-06-09 | The United States Of America As Represented By The Secretary Of The Army | Vaccines against intracellular pathogens using antigens encapsulated within biodegradble-biocompatible microspheres |
US5417986A (en) | 1984-03-16 | 1995-05-23 | The United States Of America As Represented By The Secretary Of The Army | Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres |
US4803070A (en) * | 1986-04-15 | 1989-02-07 | Ribi Immunochem Research Inc. | Immunological emulsion adjuvants for polysaccharide vaccines |
US4962091A (en) * | 1986-05-23 | 1990-10-09 | Syntex (U.S.A.) Inc. | Controlled release of macromolecular polypeptides |
US5008116A (en) * | 1988-11-14 | 1991-04-16 | Frederick Cahn | Immunostimulatory microsphere |
CA2068216C (en) * | 1989-11-13 | 1999-04-13 | Abraham J. Domb | Lipospheres for controlled delivery of substances |
AU8303691A (en) * | 1991-04-24 | 1992-12-21 | United States Of America, As Represented By The Secretary Of The Army, The | Oral-intestinal vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres |
FR2695563B1 (fr) * | 1992-09-11 | 1994-12-02 | Pasteur Institut | Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires. |
US6004763A (en) | 1992-09-11 | 1999-12-21 | Institut Pasteur | Antigen-carrying microparticles and their use in the induction of humoral or cellular responses |
DE69418699T2 (de) * | 1993-01-11 | 1999-09-30 | Dana Farber Cancer Inst Inc | Induktion der antworten zytotoxischer t-lymphozyten |
US5879687A (en) * | 1994-04-22 | 1999-03-09 | Corixa Corporation | Methods for enhancement of protective immune responses |
AU747577B2 (en) | 1997-01-30 | 2002-05-16 | Novartis Vaccines And Diagnostics, Inc. | Use of microparticles with adsorbed antigen to stimulate immune responses |
WO1999009956A1 (en) | 1997-08-29 | 1999-03-04 | Corixa Corporation | Rapid release encapsulated bioactive agents for inducing or potentiating an immune response and methods of using thereof |
US6086901A (en) | 1997-12-16 | 2000-07-11 | Chiron Corporation | Use of microparticles combined with submicron oil-in-water emulsions |
CA2731995C (en) | 1998-09-01 | 2013-05-28 | Merrion Research Iii Limited | Method for inducing a cell-mediated immune response and parenteral vaccine formulations therefor |
-
1994
- 1994-12-23 AU AU12173/95A patent/AU1217395A/en not_active Abandoned
- 1994-12-23 KR KR1019950703557A patent/KR100372375B1/ko not_active IP Right Cessation
- 1994-12-23 CN CN94191709A patent/CN1120809A/zh active Pending
- 1994-12-23 JP JP7517077A patent/JPH08507088A/ja not_active Ceased
- 1994-12-23 DK DK95903221T patent/DK0686030T3/da active
- 1994-12-23 US US08/507,323 patent/US6596278B2/en not_active Expired - Fee Related
- 1994-12-23 ES ES95903221T patent/ES2156932T3/es not_active Expired - Lifetime
- 1994-12-23 CA CA002156718A patent/CA2156718A1/en not_active Abandoned
- 1994-12-23 WO PCT/CH1994/000242 patent/WO1995017167A1/de active IP Right Grant
- 1994-12-23 DE DE59409668T patent/DE59409668D1/de not_active Expired - Fee Related
- 1994-12-23 EP EP95903221A patent/EP0686030B1/de not_active Expired - Lifetime
- 1994-12-23 AT AT95903221T patent/ATE199316T1/de not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
US20020041879A1 (en) | 2002-04-11 |
ES2156932T3 (es) | 2001-08-01 |
US6596278B2 (en) | 2003-07-22 |
WO1995017167A1 (de) | 1995-06-29 |
KR960700692A (ko) | 1996-02-24 |
AU1217395A (en) | 1995-07-10 |
CN1120809A (zh) | 1996-04-17 |
EP0686030A1 (de) | 1995-12-13 |
EP0686030B1 (de) | 2001-02-28 |
DK0686030T3 (da) | 2001-06-25 |
CA2156718A1 (en) | 1995-06-29 |
DE59409668D1 (de) | 2001-04-05 |
ATE199316T1 (de) | 2001-03-15 |
KR100372375B1 (ko) | 2003-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH08507088A (ja) | 免疫応答の増強方法 | |
Eldridge et al. | Biodegradable microspheres as a vaccine delivery system | |
Men et al. | Induction of sustained and elevated immune responses to weakly immunogenic synthetic malarial peptides by encapsulation in biodegradable polymer microspheres | |
O'hagan et al. | Biodegradable microparticles as controlled release antigen delivery systems. | |
Warren et al. | Current status of immunological adjuvants | |
US5961970A (en) | Submicron emulsions as vaccine adjuvants | |
EP0724432B1 (en) | Methods and compositions for microencapsulation of antigens for use as vaccines | |
US5603960A (en) | Preparation of microparticles and method of immunization | |
US6913767B1 (en) | Compositions for microencapsulation of antigens for use as vaccines | |
Altman et al. | Immunomodifiers in vaccines | |
US20080254134A1 (en) | Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof | |
JP2009102338A (ja) | 免疫応答を刺激するための吸着された抗原を有するマイクロパーティクルの使用 | |
US10245319B2 (en) | Lymph node-targeting nanoparticles | |
Cox et al. | Advances in adjuvant technology and application | |
GB2341801A (en) | Vaccine formulation | |
CN1128953A (zh) | 水凝胶微囊包封的疫苗 | |
Khan et al. | Immunopotentiation and delivery systems for antigens for single-step immunization: recent trends and progress | |
CA2731995C (en) | Method for inducing a cell-mediated immune response and parenteral vaccine formulations therefor | |
JP4601823B2 (ja) | 経口ワクチン組成物 | |
Lussow et al. | Towards vaccine optimisation | |
WO1994027718A1 (en) | Preparation of microparticles and method of immunization | |
Khan et al. | Antigen Delivery Systems Used to Induce Immunomodulation | |
Kirby | Formulation and characterisation of an effective particulate delivery vehicle for the novel sub-unit vaccine antigen, Ag85B-ESAT-6 | |
Men et al. | Immunological responses with biodegradable polymer microspheres | |
JP2003527413A (ja) | 粘膜表面へ投与するための医薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050823 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20051118 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060106 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060217 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060905 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20070129 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070306 |